Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070, China
Location status: Recruiting
NCT Number: NCT06925178
The aim of this study is to establish a multi-center and multi-modality imaging standard cohort of cerebrovascular disease, analyze the potential mechanisms affecting the prognosis of cerebrovascular disease based on a variety of imaging methods, and explore potential therapeutic targets.
Interested in participating?
Request Info18 year–80 year
All sexes
Observational
Beijing, Beijing Municipality, 100070, China
Location status: Recruiting
Cerebrovascular diseases are major diseases that pose a serious threat to human health and life, and have become the leading cause of death from disease among Chinese residents. Despite the best medical or surgical treatment options, many patients still suffer from functional disabilities, imposing a heavy burden on families and society. Identifying the complex and delicate changes in brain neural activity, blood flow, oxygenation, and metabolism following the occurrence of cerebrovascular diseases can not only explore the potential mechanisms underlying poor functional prognosis, but also provide a scientific basis for targeted treatment strategies. This study is a consecutive, multicenter, prospective registration study that recruits approximately 800 patients with cerebrovascular diseases (both hemorrhagic and ischemic stroke) aged 18-80 years within 7 days of onset. The study collects baseline information and imaging data including head CT, MRI, TCD, fNIRS, and ophthalmic testing. The primary endpoint event was functional outcome 3 months (mRS score). Secondary outcomes were in-hospital complications (including stroke progression, recurrence, and mortality), cognitive disorder, functional outcomes, recurrent stroke, new vascular events, and all-cause death at 3, 6 and 12 months .
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 month after enrollment
Unfavorable functional outcome is defined as mRS Score 2-5. mRS is an efficient, reliable and simple scale to assess the recovery of neurological function and disability after stroke. The high score indicates the poor neurological recovery. The minimum score (0) means no symptoms at all. The maximum (6) means death.
Time frame: duration of hospital stay(about 1 week)
In-hospital complications (including stroke progression, recurrence, and mortality).
Time frame: 6 and 12 months after enrollment
Unfavorable functional outcome is defined as the modified Rankin Scale (mRS) Score 2-5. mRS is an efficient, reliable and simple scale to assess the recovery of neurological function and disability after stroke. The high score indicates the poor neurological recovery. The minimum score (0) means no symptoms at all. The maximum (6) means death.
Time frame: 3, 6 and 12 months after enrollment
Including ischemic stroke, hemorrhagic stroke, myocardial infarction or vascular death.
Time frame: 3, 6 and 12 months after enrollment
Stroke recurrence is defined as a new focal neurological impairment that was confirmed by neuroimaging, including both ischemic stroke and hemorrhagic stroke.
Time frame: 3, 6 and 12 months after enrollment
An all-cause death is defined as a death from any cause.
Time frame: 3, 6 and 12 months after enrollment
Cognitive impairment is assessed using the MMSE and MOCA scales, with scores below 27 on the MMSE or below 26 on the MOCA indicating the presence of cognitive impairment.
Contact information is provided by the study sponsor or research team.
WENJIE WANG, PhD
CONTACT
zixiao Li, PhD
CONTACT
Beijing Tiantan Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01924312
Behavior, Body Weight
Lexington, Kentucky, United States
View Trial DetailsNCT06429332
Brain Diseases, Cardiovascular Diseases
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT06871969
Brain Diseases, Cardiovascular Diseases
Amsterdam, North Holland, Netherlands
View Trial DetailsNCT06902415
Brain Diseases, Cardiovascular Diseases
Beijing, Beijing Municipality, China
View Trial Details